Neurohumoral and hemodynamic effects of the selective endothelin antagonist darusentan in advanced chronic heart failure

Abstract

Background Endothelin antagonists represent a new approach to neurohumoral treatment in patients with chronic heart failure. In this study, the new selective endothelin-A receptor antagonist, darusentan, was compared with placebo for 3 weeks in patients with severe heart failure on top of standard treatment that included angiotensin-converting enzyme (ACE) inhibitors and β-blockers. Effects on neurohormones and hemodynamics were evaluated. Methods Consecutive patients with severe heart failure (New York Heart Association [NYHA] Grade III) were included in this neurohumoral sub-study of an international, multi-center, double-blind, placebo-controlled study of darusentan, and randomized to darusentan ( n = 23) or placebo ( n = 8). The mean left ventricular ejection fraction was 19 ± 6% at the beginning of the study. Patients were randomized to different dosage levels of darusentan (30, 100, or 300 mg) for 3 weeks. Hemodynamics were obtained by right heart Swan-Ganz catheterization at entry and end of study. Serial assessment of plasma brain natriuretic peptide (BNP), big-endothelin, and pro-atrial natriuretic peptide (pro-ANP) was performed. In the active treatment group, 1 patient died due to worsening heart failure, 1 patient received elective heart transplantation, and 2 patients stopped taking the medication due to vertigo. In the placebo group, 1 patient was excluded due to non-compliance. Results Overall, the mean dose of darusentan was 144 ± 125 mg/day (30 mg: n = 8; 100 mg: n = 4; 300 mg: n = 7). Significant benefits in hemodynamic variables were found after 3 weeks only in patients receiving darusentan (baseline vs end of study: cardiac index: 2.0 ± 0.3 vs 2.6 ± 0.5 liters/min m 2, p < 0.0001; mean pulmonary artery pressure: 35 ± 9 vs 33 ± 8 mm Hg, p < 0.05; heart rate: 79 ± 16 vs 71 ± 10 beats/min, p < 0.01). A significant reduction in mean arterial blood pressure was observed with the endothelin antagonist (baseline 80 ± 8 vs end 73 ± 8 mm Hg, p < 0.01). BNP decreased significantly in patients with darusentan (90 ± 87 at entry vs 63 ± 67 fmol/ml after 3 weeks, p < 0.01), whereas big-endothelin remained unchanged. Pro-ANP tended to decrease in the active treatment group, but did not reach statistical significance. Conclusion Significant hemodynamic and neurohumoral benefits were observed in patients with severe heart failure receiving the selective endothelin antagonist darusentan.